Overview

Rivaroxaban in Type 2 Myocardial Infarctions

Status:
Recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

This trial is the pilot phase of a randomized controlled trial to test the feasibility of recruiting patients with a type 2 myocardial infarction and randomizing them to low-dose rivaroxaban to reduce the risk of major cardiovascular events.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

University of Alberta

Treatments:

Rivaroxaban